How do magnesium, coenzyme Q10 (CoQ10), and vitamin B2 (riboflavin) improve chronic migraine?

Mechanisms of Action: Magnesium, CoQ10, and Riboflavin in Chronic Migraine

Magnesium, CoQ10, and riboflavin (vitamin B2) improve chronic migraine primarily by correcting mitochondrial energy dysfunction, reducing oxidative stress, and modulating neuroinflammatory pathways—though notably, major clinical guidelines do not recommend these supplements as first-line preventive therapy for chronic migraine. 1

Critical Context: Guidelines vs. Nutraceuticals

The most recent high-quality guidelines explicitly state that evidence-based treatment options for chronic migraine are topiramate, onabotulinumtoxinA, and CGRP monoclonal antibodies 1. Neither the 2021 Nature Reviews Neurology guideline nor the 2025 American College of Physicians guideline mention magnesium, CoQ10, or riboflavin for chronic migraine prevention 1, 2. These nutraceuticals have evidence primarily in episodic migraine, not chronic migraine.

Proposed Mechanisms of Action

Magnesium

• Mitochondrial function: Magnesium serves as a cofactor in ATP synthesis and oxidative phosphorylation, addressing the energy deficit hypothesis in migraine pathophysiology 3, 4
• Neuronal excitability: Blocks NMDA receptors and modulates calcium channels, reducing cortical spreading depression—the neurophysiological basis of migraine aura 5
• Vascular regulation: Prevents vasospasm and modulates neurotransmitter release, particularly serotonin 6
• Anti-inflammatory effects: Reduces pro-inflammatory cytokines like TNF-α that contribute to neuroinflammation during migraine attacks 4

Coenzyme Q10 (CoQ10)

• Mitochondrial electron transport: Functions as an electron carrier in the mitochondrial respiratory chain, directly improving cellular energy production 7, 8
• Antioxidant properties: Potent free radical scavenger that reduces oxidative stress, which is elevated during migraine attacks 4, 7
• Membrane stabilization: Protects neuronal cell membranes from oxidative damage 5
• Recent evidence: A 2025 review found CoQ10 supplementation decreased frequency and duration of attacks, reduced nausea, and lowered maximum pain intensity 7

Riboflavin (Vitamin B2)

• Mitochondrial energy metabolism: Essential cofactor for flavoproteins involved in the electron transport chain, particularly complexes I and II 3, 6
• Corrects energy deficiency: Addresses the hypothesis that migraine results from cerebral energy metabolism dysfunction 5, 8
• Oxidative stress reduction: Participates in glutathione recycling, enhancing antioxidant capacity 4
• Evidence level: Has Level C evidence for migraine prevention in adults with minimal adverse events 8

Shared Pathophysiological Targets

All three supplements converge on several key migraine mechanisms:

• Mitochondrial dysfunction: Migraine patients show impaired brain energy metabolism; these nutrients support ATP production 3, 4, 5
• Oxidative stress: Elevated reactive oxygen species and reduced antioxidant capacity are risk factors for migraine attacks 4, 9
• Neuroinflammation: Inflammatory cytokines increase cellular permeability and trigger migraine episodes; these supplements have anti-inflammatory properties 4
• Homocysteine metabolism: Vitamin B2 (along with B12) helps reduce homocysteine levels, which are associated with migraine attacks 3, 4

Clinical Application Caveats

Important limitations:

• Evidence is primarily from episodic migraine studies, not chronic migraine specifically 9, 8
• The 2021 guideline states "no robust data from randomized controlled trials" support many commonly used preventive treatments in chronic migraine 1
• Nutraceuticals are not FDA-regulated; purity and dosing vary significantly between products 8
• Double-blind, randomized, larger studies are needed to correctly estimate placebo effects 6
• A 2025 study found CoQ10 supplementation correlated with resolution in new daily persistent headache (a related chronic headache disorder), suggesting potential benefit 10

Practical considerations:

• These supplements may be reasonable adjuncts for patients who cannot tolerate or have failed first-line chronic migraine therapies (topiramate, onabotulinumtoxinA, CGRP antibodies) 1
• Adverse events are generally minimal, particularly compared to pharmaceutical options 9, 8
• Magnesium can cause gastrointestinal side effects 8
• Riboflavin is recommended for adults but pediatric use is not proven 8